Odimma Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Odimma Therapeutics is an early-stage biotech focused on overcoming tumor heterogeneity in oncology through a novel personalized immunotherapy platform. Its approach combines AI and synthetic DNA to design treatments that induce a cellular immune response against patient-specific tumor markers, with demonstrated anti-tumor effects in preclinical models like melanoma, colorectal, and breast cancer. The company is positioned in the rapidly evolving field of precision immuno-oncology, aiming to address hard-to-treat cancers by translating each patient's unique tumor profile into a bespoke therapeutic.

Oncology

Technology Platform

A next-generation precision immunotherapy platform combining artificial intelligence for neoantigen prediction/selection and synthetic DNA technology to create personalized therapeutic vaccines that induce a cellular immune response against patient-specific tumor markers.

Opportunities

The company is targeting the large and growing market for precision oncology, specifically in hard-to-treat cancers where current immunotherapies fail.

Its AI-driven platform could enable faster, more accurate design of personalized therapies, potentially achieving better efficacy and a competitive edge in a crowded field.

Risk Factors

Major risks include unproven clinical efficacy, the immense complexity and cost of scaling personalized therapy manufacturing, and intense competition from more advanced players in the neoantigen vaccine space.

As a pre-revenue startup, it is also highly dependent on securing future funding rounds.

Competitive Landscape

Odimma operates in the highly competitive field of personalized cancer vaccines/neoantigen therapies, competing against well-funded biotechs like BioNTech, Moderna (in oncology), Gritstone bio, and Neon Therapeutics (acquired by BioNTech), as well as large pharma partners. Differentiation will rely on the specific advantages of its AI algorithm and synthetic DNA delivery technology.

More companies in Immunotherapy / Immuno-Oncology →More companies in France →